Julian Harrison
Stock Analyst at BTIG
(4.99)
# 40
Out of 4,579 analysts
515
Total ratings
57.2%
Success rate
53.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgraded: Buy | $1.61 → $4 | $1.07 | +275.59% | 21 | Jul 27, 2026 | |
| CLYM Climb Bio | Maintained: Buy | $20 | $12.79 | +56.37% | 9 | Jul 20, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $151 | $90.20 | +67.41% | 12 | Jul 13, 2026 | |
| NKTR Nektar Therapeutics | Reiterated: Buy | $178 | $71.35 | +149.47% | 18 | Jul 13, 2026 | |
| TVRD Tvardi Therapeutics | Maintained: Buy | $15 | $2.54 | +490.55% | 7 | Jul 7, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $112 | $100.04 | +11.96% | 22 | Jul 5, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $44 | $7.79 | +464.83% | 10 | Jul 1, 2026 | |
| LQDA Liquidia | Rated: Buy | $109 | $84.42 | +29.12% | 46 | Jul 1, 2026 | |
| ABVX ABIVAX Société Anonyme | Rated: Buy | $150 → $175 | $128.00 | +36.72% | 15 | Jun 30, 2026 | |
| TBPH Theravance Biopharma | Downgraded: Hold | n/a | $16.86 | - | 16 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $21.30 | +97.18% | 4 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $19.88 | +50.91% | 32 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $137 | $134.28 | +2.03% | 27 | Jun 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.10 | +376.19% | 6 | Jun 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $17.43 | +118.01% | 24 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $6 | $4.94 | +21.46% | 16 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 → $74 | $19.95 | +270.93% | 18 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 | $19.50 | +197.44% | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.28 | +212.50% | 13 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $46 | $28.69 | +60.33% | 6 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 | $0.3021 | +231.02% | 14 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $527.94 | - | 19 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $5.06 | +235.97% | 8 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $19.70 | +209.64% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $82 | $135.56 | -39.51% | 32 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $28.56 | - | 7 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $0.8101 | n/a | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $45.02 | n/a | 8 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $10.21 | n/a | 18 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $53.61 | n/a | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $5.37 | n/a | 16 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $7.16 | n/a | 13 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $50 | $0.332 | n/a | 5 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.0002 | n/a | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $34.87 | n/a | 3 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $1.59 | n/a | 2 | Apr 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $1.08 | n/a | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $3.70 | n/a | 1 | Dec 9, 2020 |
Outlook Therapeutics
Jul 27, 2026
Upgraded: Buy
Price Target: $1.61 → $4
Current: $1.07
Upside: +275.59%
Climb Bio
Jul 20, 2026
Maintained: Buy
Price Target: $20
Current: $12.79
Upside: +56.37%
Oruka Therapeutics
Jul 13, 2026
Maintained: Buy
Price Target: $151
Current: $90.20
Upside: +67.41%
Nektar Therapeutics
Jul 13, 2026
Reiterated: Buy
Price Target: $178
Current: $71.35
Upside: +149.47%
Tvardi Therapeutics
Jul 7, 2026
Maintained: Buy
Price Target: $15
Current: $2.54
Upside: +490.55%
Spyre Therapeutics
Jul 5, 2026
Maintained: Buy
Price Target: $112
Current: $100.04
Upside: +11.96%
Cartesian Therapeutics
Jul 1, 2026
Reiterated: Buy
Price Target: $44
Current: $7.79
Upside: +464.83%
Liquidia
Jul 1, 2026
Rated: Buy
Price Target: $109
Current: $84.42
Upside: +29.12%
ABIVAX Société Anonyme
Jun 30, 2026
Rated: Buy
Price Target: $150 → $175
Current: $128.00
Upside: +36.72%
Theravance Biopharma
Jun 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $16.86
Upside: -
Jun 22, 2026
Maintained: Buy
Price Target: $42
Current: $21.30
Upside: +97.18%
Jun 22, 2026
Maintained: Buy
Price Target: $30
Current: $19.88
Upside: +50.91%
Jun 19, 2026
Reiterated: Buy
Price Target: $137
Current: $134.28
Upside: +2.03%
Jun 17, 2026
Maintained: Buy
Price Target: $10
Current: $2.10
Upside: +376.19%
Jun 10, 2026
Reiterated: Buy
Price Target: $38
Current: $17.43
Upside: +118.01%
Jun 2, 2026
Maintained: Buy
Price Target: $5 → $6
Current: $4.94
Upside: +21.46%
Jun 1, 2026
Maintained: Buy
Price Target: $39 → $74
Current: $19.95
Upside: +270.93%
May 13, 2026
Maintained: Buy
Price Target: $58
Current: $19.50
Upside: +197.44%
Apr 6, 2026
Maintained: Buy
Price Target: $4
Current: $1.28
Upside: +212.50%
Mar 25, 2026
Maintained: Buy
Price Target: $46
Current: $28.69
Upside: +60.33%
Mar 19, 2026
Maintained: Buy
Price Target: $1
Current: $0.3021
Upside: +231.02%
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $527.94
Upside: -
Feb 20, 2026
Reiterated: Buy
Price Target: $17
Current: $5.06
Upside: +235.97%
Nov 4, 2025
Reiterated: Buy
Price Target: $61
Current: $19.70
Upside: +209.64%
Nov 3, 2025
Maintained: Buy
Price Target: $82
Current: $135.56
Upside: -39.51%
Jul 31, 2025
Downgraded: Hold
Price Target: n/a
Current: $28.56
Upside: -
Mar 31, 2025
Maintained: Buy
Price Target: $14
Current: $0.8101
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $160
Current: $45.02
Upside: n/a
Dec 12, 2024
Downgraded: Hold
Price Target: n/a
Current: $10.21
Upside: n/a
Dec 2, 2024
Downgraded: Hold
Price Target: n/a
Current: $53.61
Upside: n/a
Nov 18, 2024
Upgraded: Buy
Price Target: $8
Current: $5.37
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $24
Current: $7.16
Upside: n/a
Nov 9, 2023
Rated: Buy
Price Target: $150 → $50
Current: $0.332
Upside: n/a
May 3, 2022
Initiated Coverage: Buy
Price Target: $4
Current: $0.0002
Upside: n/a
Apr 28, 2021
Maintained: Buy
Price Target: $12
Current: $34.87
Upside: n/a
Apr 27, 2021
Maintained: Buy
Price Target: $29
Current: $1.59
Upside: n/a
Apr 20, 2021
Initiated Coverage: Buy
Price Target: $51
Current: $1.08
Upside: n/a
Dec 9, 2020
Initiated Coverage: Buy
Price Target: $60
Current: $3.70
Upside: n/a